Silence Therapeutics plc (SLN)
NASDAQ: SLN · Real-Time Price · USD
2.910
-0.530 (-15.41%)
Mar 31, 2025, 1:07 PM EDT - Market open
Silence Therapeutics Revenue
In the year 2024, Silence Therapeutics had annual revenue of $43.26M with 36.71% growth. Silence Therapeutics had revenue of $25.55M in the quarter ending December 31, 2024, with 1,180.58% growth.
Revenue (ttm)
$43.26M
Revenue Growth
+36.71%
P/S Ratio
3.68
Revenue / Employee
$372,914
Employees
116
Market Cap
137.42M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 43.26M | 11.62M | 36.71% |
Dec 31, 2023 | 31.64M | 9.99M | 46.12% |
Dec 31, 2022 | 21.66M | 9.24M | 74.43% |
Dec 31, 2021 | 12.42M | 6.94M | 126.59% |
Dec 31, 2020 | 5.48M | 5.24M | 2,145.49% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
SLN News
- 26 days ago - Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference - Business Wire
- 4 weeks ago - Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - Business Wire
- 6 weeks ago - Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025 - Business Wire
- 3 months ago - Top 3 Health Care Stocks That May Explode In Q4 - Benzinga
- 4 months ago - Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting - Business Wire
- 4 months ago - Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference - Business Wire
- 4 months ago - Silence Therapeutics' Zerlasiran Has Competitive Concerns: Analyst - Benzinga